Biotech and Pharma

Botox. It's more than just a wrinkle buster

Botox by Allergan
Jb Reed | Bloomberg | Getty Images

Botox. It's more than just a wrinkle buster.

The blockbuster product is at the center of Valeant Pharmaceuticals' hostile play for Allergan, valued at $45 billion to $50 billion. Irvine, Calif.-based Allergan projects sales of Botox will rise to as much as $2.28 billion this year.

Read MoreAckman, Valeant pursuing takeover of Allergan

A little known fact: More than half of that revenue comes from therapeutic uses of Botox, rather than from cosmetic ones.

In addition to smoothing wrinkles between the eyebrows and crow's feet around the eyes, Botox is approved for uses like migraines and incontinence. And Allergan is testing it in additional therapeutic areas including depression, pain and juvenile cerebral palsy.

Read MoreCan pharma M&A cure the sector's ills?

As Allergan CEO David Pyott has put it, Botox is an entire pipeline in a single product.

Valeant's offer for Allergan
Valeant's offer for Allergan